


**(A)**

Study	DPP-4 inhibitor			Control			WMD with 95% CI	Weight (%)
	N	Mean	SD	N	Mean	SD		
Dimitrios Baltzis 2016	19	.67	2.24	21	.36	1.75	0.31 [ -0.93, 1.55]	10.16
Gyuri Kim 2017	17	-1.41	4.66	17	-1.37	5.69	-0.04 [ -3.54, 3.46]	3.45
Fang Li 2017	14	-3.4	9.54	13	1.8	10.02	-5.20 [ -12.58, 2.18]	0.96
murakami.T 2013a	17	2.3	2.4	17	-.1	1.9	2.40 [ 0.94, 3.86]	9.19
murakami.T 2018	33	3	2.19	17	-.2	1.91	3.20 [ 1.97, 4.43]	10.20
Kazufumi Nakamura 2014	24	.76	2.42	31	.98	2.41	-0.22 [ -1.51, 1.07]	9.94
Hiroshi Nomoto 2016	41	.002	13.4	49	.43	14.81	-0.43 [ -6.31, 5.46]	1.45
Norbert J. Tripolt 2018	20	.4	4.8	23	-.5	3	0.90 [ -1.46, 3.26]	5.86
Maruhashi 2016	17	.1	2.46	18	.8	2.3	-0.70 [ -2.28, 0.88]	8.66
Shigiyama 2016	29	1.33	3.45	55	.57	3.08	0.76 [ -0.68, 2.20]	9.23
Kitao 2017	46	-.51	1.29	43	-.58	1.4	0.07 [ -0.49, 0.63]	13.06
Widlansky 2017	16	.2	2.3	14	.8	2.54	-0.60 [ -2.33, 1.13]	8.02
Suzuki 2012	12	1.69	1.76	12	.54	1.52	1.15 [ -0.17, 2.47]	9.81
<b>Overall</b>							0.64 [ -0.11, 1.38]	

Heterogeneity:  $\tau^2 = 1.03$ ,  $I^2 = 66.70\%$ ,  $H^2 = 3.00$ Test of  $\theta_i = \theta_j$ :  $Q(12) = 36.03$ ,  $p = \leq 0.001$ Test of  $\theta = 0$ :  $z = 1.67$ ,  $p = 0.10$ 

Random-effects DerSimonian-Laird model

**(B)**

Study	K		WMD with 95% CI	P-value
Study population				
T2DM	10		0.11 [ -0.28, 0.51]	0.572
T2DM and Cardiovascular diseases	3		2.49 [ 1.37, 3.60]	≤0.001
Test of group differences: $Q_b(1) = 15.47$ , $p \leq 0.001$				
Control measures				
Conventional	10		0.77 [ -0.19, 1.72]	0.114
Placebo	3		0.14 [ -0.79, 1.07]	0.767
Test of group differences: $Q_b(1) = 0.85$ , $p = 0.36$				
Duration				
≥12 months	3		1.67 [ -0.58, 3.92]	0.145
< 12 months	10		0.19 [ -0.21, 0.59]	0.355
Test of group differences: $Q_b(1) = 1.61$ , $p = 0.20$				
Overall			0.64 [ -0.11, 1.38]	0.096

Heterogeneity:  $\tau^2 = 1.03$ ,  $I^2 = 66.70\%$ ,  $H^2 = 3.00$ Test of  $\theta_i = \theta_j$ :  $Q(12) = 36.03$ ,  $p \leq 0.001$ 

Random-effects DerSimonian-Laird model